The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
Abstract
Triple-negative breast cancer (TNBC) shows a higher response rate to systemic therapy compared with other breast cancer subtypes. However, the tumor differentiation of TNBC is poorer, with an early tendency to metastasis and a higher recurrence rate. Relapsed and metastatic TNBCs usually progress more rapidly, showing strong resistance to chemotherapy and radiotherapy. Due to the lack of combinatorial targeted drugs, alternative treatments fail to improve these patient's prognosis and the quality of life. Finding the Achilles' heel of TNBC is critical for patients with advanced TNBC. Here, we summarize the latest advances in the mechanisms underlying TNBC therapeutic resistance, consider how these mechanisms may affect the development and utilization of TNBC targeted drugs, and discuss the rationale of relevant signals as therapeutic targets. Also, we review the clinical trials registered in ClinicalTrial.gov for TNBC patients, which comprehensively reveals current research and development of novel TNBC targeted drugs and future trends.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Peng, M., Yang, D., Hou, Y., Liu, S., Zhao, M., Qin, Y., Chen, R., Teng, Y., & Liu, M. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1475-7 · Cited by 100
RetractedThe Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
Costa, A., Kieffer, Y., Scholer-Dahirel, A., Pelon, F., Bourachot, B., Cardon, M., Sirven, P., Magagna, I., Fuhrmann, L., Bernard, C., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.011 · Cited by 1,705
Loi, S., Sirtaine, N., Piette, F., Salgado, R., Viale, G., Van Eenoo, F., Rouas, G., Francis, P., Crown, J. P. A., Hitre, E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.0902 · Cited by 1,632
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Peng, W., Chen, J. Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M. T., Xu, C., McKenzie, J. A., Zhang, C., Liang, X., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0283 · Cited by 1,539
Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis
Zhou, W., Fong, M. Y., Min, Y., Somlo, G., Liu, L., Palomares, M. R., Yu, Y., Chow, A., O’Connor, S. T. F., Chin, A. R., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.03.007 · Cited by 1,476
CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy
Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., Krishnan, V., Hatakeyama, J., Dorigo, O., Barkal, L. J., et al. (2019) · Nature · doi:10.1038/s41586-019-1456-0 · Cited by 1,385
Marcus, L., Lemery, S. J., Keegan, P., & Pazdur, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4070 · Cited by 1,176
Senescence-associated reprogramming promotes cancer stemness
Milanovic, M., Fan, D. N. Y., Belenki, D., Däbritz, J. H. M., Zhao, Z., Yu, Y., Dörr, J. R., Dimitrova, L., Lenze, D., Monteiro Barbosa, I. A., et al. (2018) · Nature · doi:10.1038/nature25167 · Cited by 1,131
Fong, M. Y., Zhou, W., Liu, L., Alontaga, A. Y., Chandra, M., Ashby, J., Chow, A., O’Connor, S. T. F., Li, S., Chin, A. R., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3094 · Cited by 1,118
Jiang, Y.-Z., Ma, D., Suo, C., Shi, J., Xue, M., Hu, X., Xiao, Y., Yu, K.-D., Liu, Y.-R., Yu, Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.001 · Cited by 1,062
Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874
Nedeljković, M., & Damjanović, A. (2019) · Cells · doi:10.3390/cells8090957 · Cited by 870
Wang, T., Fahrmann, J. F., Lee, H., Li, Y.-J., Tripathi, S. C., Yue, C., Zhang, C., Lifshitz, V., Song, J., Yuan, Y., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.001 · Cited by 825
Self-citationXBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway
Chen, X., Iliopoulos, D., Zhang, Q., Tang, Q., Greenblatt, M. B., Hatziapostolou, M., Lim, E., Tam, W. L., Ni, M., Chen, Y., et al. (2014) · Nature · doi:10.1038/nature13119 · Cited by 817
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W., Anderson, D. J., Helgason, E., Ernst, J. A., Eby, M., Liu, J., et al. (2011) · Nature · doi:10.1038/nature09779 · Cited by 794
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Triple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 687
Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
Wang, J., Sun, J., Liu, L. N., Flies, D. B., Nie, X., Toki, M., Zhang, J., Song, C., Zarr, M., Zhou, X., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0374-x · Cited by 679
Lee, K.-M., Giltnane, J. M., Balko, J. M., Schwarz, L. J., Guerrero-Zotano, A. L., Hutchinson, K. E., Nixon, M. J., Estrada, M. V., Sánchez, V., Sanders, M. E., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.09.009 · Cited by 650
Ibrahim, Y. H., García-García, C., Serra, V., He, L., Torres-Lockhart, K., Prat, A., Anton, P., Cozar, P., Guzmán, M., Grueso, J., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0348 · Cited by 601
TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer
Bhola, N. E., Balko, J. M., Dugger, T. C., Kuba, M. G., Sánchez, V., Sanders, M., Stanford, J., Cook, R. S., & Arteaga, C. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65416 · Cited by 590
PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer
Dupuy, F., Tabariès, S., Andrzejewski, S., Dong, Z., Blagih, J., Annis, M. G., Omeroglu, A., Gao, D., Leung, S., Amir, E., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.08.007 · Cited by 558
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Wang, T., Gilkes, D. M., Takano, N., Xiang, L., Luo, W., Bishop, C. J., Chaturvedi, P., Green, J. J., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410041111 · Cited by 493
Balko, J. M., Giltnane, J. M., Wang, K., Schwarz, L. J., Young, C. D., Cook, R. S., Owens, P., Sanders, M. E., Kuba, M. G., Sánchez, V., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0286 · Cited by 482
Kim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478
Cazet, A. S., Hui, M. N., Elsworth, B. L., Wu, S. Z., Roden, D., Chan, C.-L., Skhinas, J. N., Collot, R., Yang, J., Harvey, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05220-6 · Cited by 437
Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma
Zhang, X. H.-F., Jin, X., Malladi, S., Zou, Y., Wen, Y. H., Brogi, E., Smid, M., Foekens, J. A., & Massagué, J. (2013) · Cell · doi:10.1016/j.cell.2013.07.036 · Cited by 425
Exosome-mediated transfer of miR-10b promotes cell invasion in breast cancer
Singh, R., Pochampally, R., Watabe, K., Lu, Z., & Mo, Y.-Y. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-256 · Cited by 399
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A. M., Nemsadze, G., Baird, R. D., Park, Y. H., Hall, P. S., Perren, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00368 · Cited by 391
Patel, S. A., Meyer, J. R., Greco, S. J., Corcoran, K. E., Bryan, M., & Rameshwar, P. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903143 · Cited by 363
Linderholm, B. K., Hellborg, H., Johansson, U., Elmberger, G., Skoog, L., Lehtiö, J., & Lewensohn, R. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp062 · Cited by 347
Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways
Jia, D., Lu, M., Jung, K. H., Park, J. H., Yu, L., Onuchic, J. N., Kaipparettu, B. A., & Levine, H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816391116 · Cited by 336
Zhang, Y., He, Q., Hu, Z., Feng, Y., Fan, L., Tang, Z., Yuan, J., Shan, W., Li, C., Hu, X., et al. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3211 · Cited by 331
Cancer stem cell in breast cancer therapeutic resistance
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.004 · Cited by 328
Self-citationWhole-genome sequencing of triple-negative breast cancers in a population-based clinical study
Staaf, J., Glodzik, D., Bosch, A., Vallon-Christersson, J., Reuterswärd, C., Häkkinen, J., Degasperi, A., Amarante, T. D., Saal, L. H., Hegardt, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0582-4 · Cited by 307
Samanta, D., Park, Y., Ni, X., Li, H., Zahnow, C. A., Gabrielson, E., Pan, F., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718197115 · Cited by 302
Strom, C. E., Johansson, F., Uhlen, M., Szigyarto, C. A.-K., Erixon, K., & Helleday, T. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1241 · Cited by 296
Loibl, S., Weber, K. E., Timms, K. M., Elkin, E. P., Hahnen, E., Fasching, P. A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy460 · Cited by 295
Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance
Xiong, G., Stewart, R. L., Chen, J., Gao, T., Scott, T. L., Samayoa, L. M., O’Connor, K., Lane, A. N., & Xu, R. (2018) · Nature Communications · doi:10.1038/s41467-018-06893-9 · Cited by 274
Lu, H., Samanta, D., Xiang, L., Zhang, H., Hu, H., Chen, I., Bullen, J. W., & Semenza, G. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1513433112 · Cited by 269
Lim, S.-O., Li, C.-W., Xia, W., Lee, H.-H., Chang, S.-S., Shen, J., Hsu, J. L., Raftery, D., Djukovic, D., Gu, H., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2478 · Cited by 266
Hashimoto, K., Ochi, H., Sunamura, S., Kosaka, N., Mabuchi, Y., Fukuda, T., Yao, K., Kanda, H., Ae, K., Okawa, A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1717363115 · Cited by 260
Chaturvedi, P., Gilkes, D. M., Takano, N., & Semenza, G. L. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406655111 · Cited by 226
Amiri-Kordestani, L., Basseville, A., Kurdziel, K., Fojo, A. T., & Bates, S. E. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.02.002 · Cited by 219
Stevic, I., Müller, V., Weber, K., Fasching, P. A., Karn, T., Marmé, F., Schem, C., Stickeler, E., Denkert, C., van Mackelenbergh, M., et al. (2018) · BMC Medicine · doi:10.1186/s12916-018-1163-y · Cited by 212
Roux, C., Jafari, S. M., Shinde, R., Duncan, G., Cescon, D. W., Silvester, J., Chu, M. F., Hodgson, K., Berger, T., Wakeham, A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819473116 · Cited by 207
An Integrated Genomic Screen Identifies LDHB as an Essential Gene for Triple-Negative Breast Cancer
McCleland, M. L., Adler, A. S., Shang, Y., Hunsaker, T., Truong, T., Peterson, D., Torres, E., Li, L., Haley, B., Stephan, J.-P., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1098 · Cited by 191
Sarmiento-Salinas, F. L., Delgado-Magallón, A., Montes-Alvarado, J. B., Ramírez-Ramírez, D., Flores-Alonso, J. C., Cortés-Hernández, P., Reyes-Leyva, J., Herrera-Camacho, I., Anaya-Ruiz, M., Pelayo, R., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00480 · Cited by 180
Liu, S., González‐Prieto, R., Zhang, M., Geurink, P. P., Kooij, R., Iyengar, P. V., van Dinther, M., Bos, E., Zhang, X., Dévédec, S. E. L., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1373 · Cited by 175
Lefort, S., Joffre, C., Kieffer, Y., Givel, A.-M., Bourachot, B., Zago, G., Bieche, I., Dubois, T., Meseure, D., Vincent-Salomon, A., et al. (2014) · Autophagy · doi:10.4161/15548627.2014.981788 · Cited by 173
ITGB4-mediated metabolic reprogramming of cancer-associated fibroblasts
Sung, J. S., Kang, C. W., Kang, S., Jang, Y., Chae, Y. C., Kim, B. G., & Cho, N. H. (2020) · Oncogene · doi:10.1038/s41388-019-1014-0 · Cited by 172
Pawlowska, E., Szczepanska, J., & Blasiak, J. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7286737 · Cited by 169
Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer
Ribatti, D., Nico, B., Ruggieri, S., Tamma, R., Simone, G., & Mangia, A. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.07.002 · Cited by 166
Lu, L., Dong, J., Wang, L., Xia, Q., Zhang, D., Kim, H., Yin, T., Fan, S., & Shen, Q. (2018) · Oncogene · doi:10.1038/s41388-018-0340-y · Cited by 166
Lehmann, B. D., Abramson, V. G., Sanders, M. E., Mayer, E. L., Haddad, T. C., Nanda, R., Poznak, C. H. V., Storniolo, A. M., Nangia, J. R., Ericsson, P. I. G., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2170 · Cited by 160
Stover, D. G., del Alcazar, C. R. G., Brock, J. E., Guo, H., Overmoyer, B. A., Balko, J. M., Xu, Q., Bardia, A., Tolaney, S. M., Gelman, R. S., et al. (2018) · npj Breast Cancer · doi:10.1038/s41523-018-0060-z · Cited by 154
Zhang, D., Sun, B., Zhao, X., Ma, Y., Ji, R., Gu, Q., Dong, X., Li, J., Liu, F., Jia, X., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-207 · Cited by 132
Tseng, C.-W., Kuo, W., Chan, S., Chan, H., Chang, K., & Wang, L. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2906 · Cited by 131
Leconet, W., Chentouf, M., du Manoir, S., Chevalier, C., Sirvent, A., Aït-Arsa, I., Busson, M., Jarlier, M., Radosevic‐Robin, N., Theillet, C. G., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1316 · Cited by 114
Barton, V. N., Christenson, J. L., Gordon, M. A., Greene, L. I., Rogers, T. J., Butterfield, K., Babbs, B. L., Spoelstra, N. S., D’Amato, N. C., ELIAS, A. D., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3240 · Cited by 112
van Eijk, M., Boosman, R. J., Schinkel, A. H., Huitema, A. D. R., & Beijnen, J. H. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03905-3 · Cited by 107
Brinkman, A. M., Chen, G., Wang, Y., Hedman, C. J., Sherer, N. M., Havighurst, T. C., Gong, S., & Xu, W. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.05.041 · Cited by 104
ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer
Tu, X., Kahila, M. M. H., Zhou, Q., Yu, J., Kalari, K. R., Wang, L., Harmsen, W. S., Yuan, J., Boughey, J. C., Goetz, M. P., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0470 · Cited by 104
Nanodiamond–Mitoxantrone Complexes Enhance Drug Retention in Chemoresistant Breast Cancer Cells
Toh, T. B., Lee, D.-K., Hou, W., Abdullah, L. N., Nguyen, J., Ho, D., & Chow, E. K. (2014) · Molecular Pharmaceutics · doi:10.1021/mp5001108 · Cited by 99
Lu, H., Tran, T. M. L., Park, Y., Chen, I., Lan, J., Xie, Y., & Semenza, G. L. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0270 · Cited by 99
Wang, B., Zhang, Y., Ye, M., Wu, J., Ma, L., & Chen, H. (2019) · Current Drug Metabolism · doi:10.2174/1389200220666190819151946 · Cited by 96
Sami, E., Paul, B. T., Koziol, J. A., & ElShamy, W. M. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2374 · Cited by 96
Doherty, M. R., Parvani, J. G., Tamagno, I., Junk, D. J., Bryson, B. L., Cheon, H. J., Stark, G. R., & Jackson, M. W. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1136-x · Cited by 79
Beatty, A., Fink, L. S., Singh, T., Strigun, A., Peter, E., Ferrer, C. M., Nicolas, É., Cai, K. Q., Moran, T. P., Reginato, M. J., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0407 · Cited by 72
Bardia, A., Parton, M., Kümmel, S., Estévez, L. G., Huang, C.-S., Cortés, J., Ruiz-Borrego, M., Telli, M. L., Martin-Martorell, P., López, R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.8392 · Cited by 72
Johnatty, S. E., Beesley, J., Gao, B., Chen, X., Lu, Y., Law, M. H., Henderson, M. J., Russell, A. J., Hedditch, E. L., Emmanuel, C., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.07.107 · Cited by 71
Carlisi, D., Blasio, A. D., Drago‐Ferrante, R., Fiore, R. D., Buttitta, G., Morreale, M., Scerri, C. A., Vento, R., & Tesoriere, G. (2017) · Cell Death Discovery · doi:10.1038/cddiscovery.2017.78 · Cited by 69
The Relationship Between Mismatch Repair Deficiency and PD-L1 Expression in Breast Carcinoma
Mills, A. M., Dill, E. A., Moskaluk, C. A., Dziegielewski, J., Bullock, T. N., & Dillon, P. M. (2017) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000949 · Cited by 61
Wen, Y. H., Brogi, E., Zeng, Z., Akram, M. M., Catalano, J., Paty, P. B., Norton, L., & Shia, J. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3182627787 · Cited by 53
EGFL9 promotes breast cancer metastasis by inducing cMET activation and metabolic reprogramming
Meng, F., Wu, L., Dong, L., Mitchell, A. V., Block, C. J., Liu, J., Zhang, H., Lu, Q., Song, W., Zhang, B., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-13034-3 · Cited by 51
Zhang, C., Wang, S., Israel, H., Yan, S. X., Horowitz, D. P., Crockford, S., Gidea-Addeo, D., Chao, K., Kalinsky, K. M., & Connolly, E. P. (2015) · SpringerPlus · doi:10.1186/s40064-015-1116-2 · Cited by 38
Lee, K. J., Piett, C. G., Andrews, J., Mann, E. K., Nagel, Z. D., & Gassman, N. R. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223725 · Cited by 37
Raguz, S., Adams, C. E., Masrour, N., Rasul, S., Papoutsoglou, P., Hu, Y., Cazzanelli, G., Zhou, Y., Patel, N. R., Coombes, R. C., et al. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.10.020 · Cited by 34
Cecil, D. L., Slota, M., O'Meara, M. M., Curtis, B. C., Gad, E. A., Dang, Y., Herendeen, D. R., Rastetter, L., & Disis, M. L. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1678 · Cited by 34
Meyer, F., Becker, S., Classen, S., Parplys, A. C., Mansour, W. Y., Riepen, B., Timm, S., Ruebe, C., Jasin, M., Wikman, H., et al. (2020) · Cells · doi:10.3390/cells9010238 · Cited by 34
Hou, Y., Nitta, H., Parwani, A. V., & Li, Z. (2019) · Human Pathology · doi:10.1016/j.humpath.2018.12.007 · Cited by 25
Yang, Y., & Yee, D. (2015) · Cancer Research · doi:10.1158/1538-7445.am2015-1207 · Cited by 5
Cited by
Chen, Q., Zhang, M., Huang, H., Dong, C., Dai, X., Feng, G., Lin, L., Sun, D., Yang, D., Xie, L., et al. (2023) · Advanced Science · doi:10.1002/advs.202206244 · Cited by 83
Si, Y., Yue, J., Liu, Z., Li, M., Du, F., Wang, X., Dai, Z., Hu, N., Ju, J., Gao, S., et al. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s297933 · Cited by 52
Zhang, H., Zhu, S., Zhou, H., Li, R., Xia, X., & Xiong, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1098357 · Cited by 46
Liu, R., Wang, R., Zhao, M., Liu, Y., Zhu, X., Wu, X., Du, S., Gu, Z., & Du, J. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101997 · Cited by 23
Yue, L., Geng, F., Jin, J., Li, W., Liu, B., Du, M., Gao, X., Lü, J., & Pan, X. (2024) · Biotechnology Journal · doi:10.1002/biot.202400428 · Cited by 14
Metadata
- Authors
- Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 497
- Pages
- 100-111
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W3092655545
- Cited by
- 283
- References
- 89
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.